<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=384506&amp;fmt=gif">
Skip to content
Sign Up
    September 15, 2023

    Recorded Webinar: Drug Design Trends in the Age of AI

    Don't miss this opportunity to explore the intriguing world of computer-guided drug design as we compare two innovative methodologies: fragment-based drug design and full molecule-based drug design. Our esteemed panelists will delve into these two approaches' strengths, limitations, and future prospects while uncovering potential synergies.

    This is an engaging webinar where we unravel the promises and possibilities offered by these cutting-edge approaches.

    Download Slides (PDF)

    Featuring these leading scientists...


    Barry Bunin, PhD

    CEO, Collaborative Drug Discovery

    Barry Bunin founded CDD in 2004 to pioneer CDD Vault, a hosted research data management system. Prior to CDD, he was an Entrepreneur in Residence with Eli Lilly, as well as the founding CEO, President, & CSO of Libraria (now Eidogen-Sertanty). 

    On the scientific side, Dr. Bunin is an expert in cheminformatics and combinatorial chemistry, and has written two books in those fields. He is also on the patent of Kyprolis, a selective proteasome inhibitor for treating multiple myeloma.

    Dr. Bunin received his B.A. from Columbia University and his Ph.D. from UC Berkeley, where he synthesized and tested the initial 1,4-benzodiazepine libraries with Professor Jonathan Ellman.


    Eric Martin, PhD

    Director, Computational Chemistry at Novartis

    Eric Martin has a Ph.D. in physical organic chemistry from Yale University. He has worked in computational drug design and herbicide design for 40 years at Dow, DowElanco, Chiron and Novartis. He is currently developing novel methodologies for two areas of drug discovery: 1) Developing “Profile-QSAR”, a massively multitask machine learning method that builds experimental-quality virtual screening models for over 9000 IC50 assays, and 2) “rational oral bioavailability design” during lead optimization, by applying global sensitivity analysis to physiologically-based pharmacokinetics simulations. Eric was awarded the lifetime title of Novartis Leading Scientist for the former.


    Daniel Erlanson, PhD

    SVP, Innovation and Discovery at Frontier Medicines

    Daniel Erlanson is an expert in fragment-based and covalent drug discovery. Prior to Frontier, Dan co-founded Carmot Therapeutics, where he developed drug discovery technologies and led chemistry efforts that resulted in three clinical-stage molecules and partnerships with biotech companies including Amgen and Genentech. One of the molecules advanced by Amgen is LUMAKRAS™ (sotorasib), the first FDA and EMA approved inhibitor of KRASG12C, a previously undruggable target.  

    Dr. Erlanson earned his Ph.D. in Chemistry from Harvard University in the laboratory of Gregory L. Verdine.

    Tag(s): CDD Blog , Webinars

    Other posts you might be interested in

    View All Posts
    CDD Blog
    8 min   June 13, 2024
    Drug Discovery Industry Roundup with Barry Bunin — June, 13 2024
    Read More
    CDD Vault Updates
    4 min   June 10, 2024
    CDD Vault Update (June 2024): Add a Title, Arbitrary Lines, Add/Remove Whiskers in Dose-response Plots, Request More Bioisostere Hits, and Indent Lists in ELN
    Read More
    CDD Vault Updates
    3 min   May 24, 2024
    CDD Vault Update (May 2024 #3): Resume Vault Session & Deep Learning Enhancements: More Hits, Persist Calculated Properties
    Read More